Bridgebio Pharma Stock News

The stock price of BridgeBio Pharma Inc (NASDAQ: BBIO) fell by over 60% pre-market today. This is why it happened.

BridgeBio Pharma Inc. BBIO, +5.84% said Monday that a Phase 3 study of its acoramidis for the treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) failed to meet its primary e

BridgeBio Pharma, Inc. (NASDAQ:BBIO) was the target of unusually large options trading on Thursday. Investors purchased 21,583 put options on the stock. This is an increase of approximately 996% compared to the typical daily volume of 1,969 put options. BBIO has been the topic of several recent analyst reports. SVB Leerink cut their target price […]

In last trading session, BridgeBio Pharma Inc. (NASDAQ:BBIO) saw 1.51 million shares changing hands with its beta currently measuring 0. Companys recent per share price level of $38.38 trading at -$3.98 or -9.40% at ring of the bell on the day assigns it a market valuation of $4.91B. That closing price of BBIOs stock is BridgeBio Pharma Inc. (NASDAQ:BBIO)s 12-Month Price Target Currently Stands At $91.00 Read More »

BridgeBio has been on my radar for over a year now, but the conditions never aligned to start a position. The recent sell-off in the SMID caps has provided an opportunity to buy at a tolerable valuati

BridgeBio Pharma, Inc. (NASDAQ:BBIO) shares shot up 8.1% during mid-day trading on Friday . The company traded as high as $40.20 and last traded at $40.04. 7,503 shares were traded during trading, a decline of 99% from the average session volume of 884,662 shares. The stock had previously closed at $37.05. A number of brokerages []

BridgeBio Pharma Inc. (NASDAQ:BBIO) shares, rose in value on Thursday, 12/16/21, with the stock price down by -4.46% to the previous day’s close as strong demand from buyers drove the stock to $37.05. Actively observing the price movement in the last trading, the stock closed the session at $38.78, falling within a range of $36.72 … Things To Consider If You’re Thinking Of Investing In BridgeBio Pharma Inc. (NASDAQ: BBIO) Read More »

BridgeBio Pharma (NASDAQ:BBIO) and Decibel Therapeutics (NASDAQ:DBTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership. Earnings & Valuation This table compares BridgeBio Pharma and Decibel Therapeutics gross revenue, earnings per share []

Fisher Asset Management LLC purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 569,265 shares of the companys stock, valued at approximately $26,681,000. A number of other hedge funds and other institutional investors have []

BridgeBio Pharma (NASDAQ:BBIO) and Novan (NASDAQ:NOVN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings. Analyst Recommendations This is a breakdown of current ratings and target prices for BridgeBio Pharma and Novan, []

During the last session, BridgeBio Pharma Inc. (NASDAQ:BBIO)s traded shares were 0.88 million. At the end of the trading day, the stocks price was $40.74, reflecting an intraday loss of -0.49% or -$0.2. The 52-week high for the BBIO share is $73.50, that puts it down -80.41 from that peak though still a striking 3.46% We Just Learned Something New! After BridgeBio Pharma Inc. (NASDAQ: BBIO)s -11.63% Loss This Week Read More »

Investors need to pay close attention to BridgeBio (BBIO) stock based on the movements in the options market lately.

BridgeBio Pharma (NASDAQ:BBIO) had its price target lowered by investment analysts at SVB Leerink from $68.00 to $66.00 in a report released on Friday, Benzinga reports. The brokerage currently has an outperform rating on the stock. SVB Leerinks target price indicates a potential upside of 54.75% from the stocks previous close. BBIO has been the []